Amgen's stock saw a significant rise, fueled by positive market sentiment and strong performance indicators.
Amgen Inc. (NASDAQ:AMGN) experienced a 2.60% increase in its stock price during yesterday's trading session, closing at CA$413.08. This rise comes alongside favorable commentary from market analysts and solid performance metrics from the company.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$223.32B
P/E
25.0x
Div. yield
2.43%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+0.04%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 9, 2026
Wall Street analysts forecast AMGN stock price to fall 3.9% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$391.46
-3.9% Upside
Previously C$390.94 on Oct 5, 2026
Current Price
C$407.44
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.1%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$487.10
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$432.43 | C$376.50 – C$496.67 |
| 60 trading days | C$458.95 | C$377.31 – C$558.25 |
| 90 trading days | C$487.10 | C$383.21 – C$619.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider Amgen's strong revenue growth and the potential for its newer drugs to offset declines in older products, making it a compelling option in the biotech sector.
Amgen's Revenue Grew by 10% Year-Over-Year
The company's second-quarter revenue reached about $10.1 billion, reflecting strong demand for its newer therapies.
Bull case
Amgen's newer medicines, like Repatha and Evenity, have seen impressive sales growth, contributing to a 10% year-over-year revenue increase. This trend indicates a positive outlook for the company as it continues to innovate.
Bear case
Despite recent gains, Amgen faces challenges from declining sales of older products due to biosimilar competition. If not managed effectively, this could impact overall profitability.
Strong Performance Metrics
Advertisement
Amgen reported a 10% revenue increase for the second quarter, reaching approximately $10.1 billion. This growth was largely driven by the success of newer medications like Repatha and Evenity, which saw sales increases of 37% and 38%, respectively. Such performance highlights the company's ability to innovate and adapt in a competitive market.
Market Analyst Insights
Analysts have noted Amgen's recent performance, with Jim Cramer highlighting the company's position in the market during a recent episode of Mad Money. He pointed out that Amgen's stock has shown a remarkable catch-up trade, gaining 16% compared to the Dow Jones Industrial Average's performance. This positive sentiment could further boost investor confidence in the company's future prospects.
Challenges Ahead
Despite the positive momentum, Amgen must navigate challenges such as declining sales from older products like Prolia and Xgeva, which have faced significant competition from biosimilars. The company’s ability to maintain its growth trajectory will depend on how effectively it can manage these declines while continuing to promote its newer therapies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
